Runt-Related Transcription Factor 2 Induction During Differentiation of Wharton's Jelly Mesenchymal Stem Cells to Osteoblasts Is Regulated by Jumonji AT-Rich Interactive Domain 1B Histone Demethylase.
Francisco BustosHugo SepulvedaCatalina P PrietoMargarita CarrascoLorena DíazJosé PalmaJosé LattusMartín MontecinoVerónica PalmaPublished in: Stem cells (Dayton, Ohio) (2017)
Novel bone regeneration approaches aim to obtain immature osteoblasts from somatic stem cells. Umbilical cord Wharton's jelly mesenchymal stem cells (WJ-MSCs) are an ideal source for cell therapy. Hence, the study of mechanisms involved in WJ-MSC osteoblastic differentiation is crucial to exploit their developmental capacity. Here, we have assessed epigenetic control of the Runt-related transcription factor 2 (RUNX2) osteogenic master regulator gene in WJ-MSC. We present evidence indicating that modulation of RUNX2 expression through preventing Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase activity is relevant to enhance WJ-MSC osteoblastic potential. Hence, JARID1B loss of function in WJ-MSC results in increased RUNX2/p57 expression. Our data highlight JARID1B activity as a novel target to modulate WJ-MSC osteoblastic differentiation with potential applications in bone tissue engineering. Stem Cells 2017;35:2430-2441.
Keyphrases
- mesenchymal stem cells
- transcription factor
- umbilical cord
- cell therapy
- stem cells
- bone regeneration
- genome wide identification
- bone marrow
- dna methylation
- tissue engineering
- dna binding
- poor prognosis
- vascular smooth muscle cells
- copy number
- gene expression
- genome wide
- binding protein
- risk assessment
- human health
- climate change
- soft tissue